For investors

We would like to thank Add Value Language Centre for translating the text used in the above material.

About us

POLBIONICA is a spin-off company established by the Foundation of Research and Science Development, which is a leader of BIONIC consortium. Consortium is implementing the project as part of the STRATEGMED program funded by the Polish National Center for Research and Development which aims to 3Dbioprint bionic pancreas – with living cells and tissues. On March 14 th 2019, scientific team bioprinted the world’s first prototype of a bionic pancreas withvascular system.

Our Mission

POLBIONICA is developing the first bionic pancreas suitable for transplantation, based on bioprinted 3D cell-laiden bioinks, functional vessels and pancreatic islets. The organ will restore the body ability to regulate blood sugar levels and revolutionize the treatment of diabetes. At that moment scientific team has the ability to bioprint living organ with diameters 3x5x3,5 cm – which consists of more than 600 000 Islets equivalents (retrieved from the donor) – the amount which is suitable to cure man from diabetes. In the next step, it is planned to replace the pancreatic islets by stem cells-derived alpha and beta cells. With this approach, the patient does not have to wait for donor cells as it uses pluripotent stem cells from patients’ own tissues. Our mission is to introduce 3D bioprinting of the bionic pancreas to clinical practice worldwide. Within 3 years this technology can enter clinical trial phase.

WE HAVE RECEIVED THE SEAL OF EXCELLENCE IN H2020’S SME INSTRUMENT PHASE 1.

key facts

More than 40 million people worldwide suffer from type 1 diabetes, and in Europe alone there are about 7 million. 700,000 of them have serious complications. The WHO says that by 2030 diabetes will be the seventh most common cause of death in the world. The only method leading to a complete cure is a pancreas or pancreatic islet transplantation. Only around 250 transplantations are carried out annually in Europe* and around 200 people die while waiting for a transplant. Transplantation in its present form does not solve the problem of organ shortage. In order to meet the difficulties posed by the existing concept of fighting the disease, the idea of creating a bionicpancreas was born.

Key Advantage

Two types of bio-inks

bioink A – for bioprinting bionic pancreas body
bioink B – for bioprinting vasculature

NOVEL BIOREACTOR

 device dedicated to ensure the physiologically relevant conditions for organs after a bio-printing process.

G-CODE

file with printer commands to bioprint bionic pancreas, know-how to do that.

bioprinting market and  Preclinical studies

It is estimated that by 2026 the value of the bioprinting market will increase 4-fold to over $4 billion with the Compound Annual Rate of Growth at 19. 5%. The value of the preclinical studies market is currently estimated at $3.24 billion. By 2026, this value will have risen to $6.6 billion. The largest component of the market are toxicological studies, which will dominate this market segment. 50% failures in the transition to the clinical phase are related to toxicological tests. There is no need to apply GLP standards to this phase of testing.

Our Team

POLBIONICA is made up of world-class experts in many fields. Doctors,  biotechnologists, chemists, mechatronics, specialists in 3D printing and bioprinting and IT specialists. The team leader is Michał Wszola, MD PhD, transplant and general surgeon, inventor and entrepreneur. Repeatedly awarded in Poland and abroad and decorated with theGolden Cross of Merit of the President of the Republic of Poland.

Contact Us

Michał Wszoła MD, PhD
cEO of Polbionica 
michal.wszola@polbionica.com